Format

Send to

Choose Destination
Br J Cancer. 2005 Feb 28;92(4):628-30.

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.

Author information

1
Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK. juan.valle@christie-tr.nwest.nhs.uk

Abstract

Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.

PMID:
15700038
PMCID:
PMC2361887
DOI:
10.1038/sj.bjc.6602394
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center